Eslicarbazepine acetate

Generic Name
Eslicarbazepine acetate
Brand Names
Aptiom, Zebinix
Drug Type
Small Molecule
Chemical Formula
C17H16N2O3
CAS Number
236395-14-5
Unique Ingredient Identifier
BEA68ZVB2K
Background

Eslicarbazepine acetate (ESL) is an anticonvulsant medication approved for use in Europe, the United States and Canada as an adjunctive therapy for partial-onset seizures that are not adequately controlled with conventional therapy. Eslicarbazepine acetate is a prodrug that is rapidly converted to eslicarbazepine, the primary active metabolite in the body. E...

Indication

Eslicarbazepine acetate is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.

Associated Conditions
Partial-Onset Seizures
Associated Therapies
-
Clinical Trials
Related News

A Study of a Drug to be Used in Addition With Another Drug to Treat Adults With Uncontrolled Partial-onset Seizures

First Posted Date
2017-04-17
Last Posted Date
2020-06-16
Lead Sponsor
Sumitomo Pharma America, Inc.
Target Recruit Count
102
Registration Number
NCT03116828
Locations
🇺🇸

Temple University Lewis Katz School of Medicine, Philadelphia, Pennsylvania, United States

🇺🇸

Aston Ambulatory Care Center, Dallas, Texas, United States

🇺🇸

Northwestern Medical Group, Deparment of Neurology, Chicago, Illinois, United States

and more 52 locations

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

Phase 3
Withdrawn
Conditions
Epilepsy
Interventions
Drug: Eslicarbazepine acetate
First Posted Date
2017-04-11
Last Posted Date
2018-01-16
Lead Sponsor
Sumitomo Pharma America, Inc.
Registration Number
NCT03108729
Locations
🇺🇸

Child Neurology Specialists / Clinical Research Center of Nevada, LLC, Henderson, Nevada, United States

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

Phase 1
Completed
Conditions
Epilepsy
Interventions
Drug: Eslicarbazepine acetate
Drug: Lamotrigine
First Posted Date
2014-11-05
Last Posted Date
2014-11-05
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
32
Registration Number
NCT02283801

The Effect of BIA 2-093 on the Steady-state Pharmacokinetic Profile of Phenytoin in Patients

First Posted Date
2013-06-17
Last Posted Date
2014-02-27
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
4
Registration Number
NCT01878578
Locations
🇵🇹

Neurology Department, Hospital of Santa Maria, Lisbon, Portugal

Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) in Acute Manic Episodes Associated With Bipolar I Disorder

First Posted Date
2013-04-02
Last Posted Date
2014-03-27
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
161
Registration Number
NCT01822678

Eslicarbazepine Acetate as Add-On Treatment to One Baseline Antiepileptic Drug (ESLADOBA)

Completed
Conditions
Epilepsy
Interventions
Drug: ESL
First Posted Date
2012-02-14
Last Posted Date
2017-01-06
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
56
Registration Number
NCT01532726
Locations
🇵🇹

Hospital Fernando da Fonseca, Lisboa, Portugal

Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients

Phase 3
Completed
Conditions
Epilepsy
Interventions
Drug: Eslicarbazepine Acetate
First Posted Date
2011-08-24
Last Posted Date
2017-08-07
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
72
Registration Number
NCT01422720
Locations
🇵🇹

Centro Hospitalar de Trás-os -Montes e Alto-Douro, EPE - Hospital de São Pedro - Serviço de Neurologia, Vila Real, Portugal

🇷🇴

Sc Clubul Sanatatii Srl, Campulung Muscel, Romania

🇷🇴

Spitalul Clinic de Neuropsihiatrie Craiova, Craiova; Jud. Dolj, Romania

and more 45 locations

Eslicarbazepine Acetate (BIA 2 093) as Therapy for Refractory Partial Seizures in Children

First Posted Date
2009-10-02
Last Posted Date
2018-11-13
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
304
Registration Number
NCT00988156
Locations
🇦🇹

Ambulanz für Neuropädiatrie und Entwicklungsdiagnostik, Med. Univ. Graz, Graz, Austria

🇭🇷

Clinical hospital Osjek Pediatric clinic, neuropediatric department, Osijek, Croatia

🇩🇪

Epilepsiezentrum Kehl-Kork Kinderklinik Anfallsambulanz für Kinder und jugendliche, Kehl-Kork, Germany

and more 87 locations

Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects

Phase 1
Completed
Conditions
Epilepsy
Interventions
Drug: Eslicarbazepine acetate
Drug: Simvastatin
First Posted Date
2009-10-01
Last Posted Date
2015-01-13
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
30
Registration Number
NCT00987558
Locations
🇫🇷

Biotrial, 7-9 rue Jean-Louis Bertrand, Rennes, France

Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia

First Posted Date
2009-09-22
Last Posted Date
2014-10-29
Lead Sponsor
Bial - Portela C S.A.
Target Recruit Count
567
Registration Number
NCT00981227
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy